Amgen Inc.

Fang-Tsao Hong

Seifu Tadesse

Celia Dominguez

Andrew Stewart Tasker

Nuria A Tamayo

John Gordon Allen

Xianghong Wang

Matthew Paul Bourbeau

Qingping Zeng

Guomin Yao

Qingyian Liu

Christopher Harold Fotsch

Chester Chenguang Yuan

Nianhe Han

James Richard Falsey

Matthew Lee

Xin Huang

George Erich Wohlhieter

James Thomas Rider

Kurt E Weiler

Mark Henry Norman

Patricia Lopez

Longbin Liu

Dawei Zhang

Aiwen Li

Andreas Reichelt

Adrian Leonard Smith

Noel D'Angelo

Kelvin K C Sham

Hongyu Liao

Vellarkad N Viswanadhan

Jennifer Rebecca Allen

Holger Monenschein

Bin Wu

Anthony B Reed

Nobuko Nishimura

Robert Michael Rzasa

Shon Booker

Kevin Chao Yang

Ryan D White

Liping H Pettus

Victor J Cee

Michael J Frohn

Brian Alan Lanman

Ryan Paul Wurz

Aaron C Siegmund

Leslie Phillip Miranda

Laurie B Schenkel

Karina Romero

Jason Brooks Human

Philip R Olivieri

Bradley J Herberich

Zihao Hua

Yunxin Y Bo

Oleg Epstein

Xiao Mei Zheng

Guo-Qiang Cao

Essa Hu Harrington

John Stellwagen

Irwin Chen

Claire L M Jackson

Kristin L Andrews

Jason C Long

Martin H Goldberg

Su Chong

Adrian L Smith

Noel D'angelo

Claire L Jackson

Matthew R Lee

Novel peptides that bind to human PAC1 are provided. These peptides that are antagonists of PAC1 are useful in a number of PAC1 related disorders, including the treatment and/or prevention of headache disorders, including migraine, such as acute migraine.

Peptide PAC1 antagonists

The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A, A, A, R, R, R, R, X, Y, n and o of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and corresponding uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formula II and sub-formula embodiments thereof, compounds of Formula III, intermediates and processes and methods useful for the preparation of compounds of Formulas I-III, and sub-Formulas thereof.

Fused multi-cyclic sulfone compounds as inhibitors of beta-secretase and methods of use thereof

The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt thereof; methods of treating diseases or conditions, such as cancer, using the compounds; and pharmaceutical compositions containing the compounds, wherein the variables are as defined herein.

Inhibitors of PI3 kinase and/or mTOR

The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt thereof; methods of treating diseases or conditions, such as cancer, using the compounds; and

The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including inflammation and related conditions. The compounds have a general Formula I wherein A, A, B, Rand Rare defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, uses of such compounds and compositions for treatment of kinase mediated diseases including rheumatoid arthritis, psoriasis and other inflammation disorders, as well as intermediates and processes useful for the preparation of compounds of Formula I.

Thieno-[2,3-d]pyrimidine and thieno-pyridazine compounds and methods of use

The invention relates to methods of using thiazole compounds of Formula I and Formula II and compositions thereof for treating diseases mediated by protein kinase B (PKB) such as cancer and other proliferative disorders where the variables have the definitions provided herein. 

Thiazole compounds and methods of use

The present invention comprises a new class of compounds useful for the prophylaxis and treatment of pro-inflammatory cytokine mediated diseases, including inflammation and related conditions. The compounds have a general Formula I wherein s, T, R, R, Rand Rare defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, methods of use such as treatment of p38 mediated diseases by administering the compounds of Formula I or compositions including the compounds of Formula I, and intermediates and processes useful for the preparation of compounds of Formula I.

2-quinazolinone compounds and methods of use

The invention relates to thiazole compounds of Formula I and Formula II and compositions thereof useful for treating diseases mediated by protein kinase B (PKB) where the variables have the definitions provided herein. The invention also relates to the therapeutic use of such thiazole compounds and compositions thereof in treating disease states associated with abnormal cell growth, cancer, inflammation, and metabolic disorders.

Thiadiazole modulators of PKB

The invention relates to heterocyclic compounds of Formula I and compositions thereof useful for treating diseases mediated by protein kinase B (PKB) where the variables have the definitions provided herein.  The invention also relates to the therapeutic use of such compounds and compositions thereof in treating disease states associated with abnormal cell growth, cancer, inflammation, and metabolic disorders.

Heterocyclic modulators of PKB

The present invention relates to pyrimidinones and pyridones and derivatives thereof, and pharmaceutically acceptable salts thereof. Also included is a method of treatment of inflammation, rheumatoid arthritis, Pagets disease, osteoporosis, multiple myeloma, uveititis, acute or chronic myelogenous leukemia, pancreatic &#x3b2; cell destruction, osteoarthritis, rheumatoid spondylitis, gouty arthritis, inflammatory bowel disease, adult respiratory distress syndrome (ARDS), psoriasis, Crohn's disease, allergic rhinitis, ulcerative colitis, anaphylaxis, contact dermatitis, asthma, muscle degeneration, cachexia, Reiter's syndrome, type I diabetes, type II diabetes, bone resorption diseases, graft vs. host reaction, Alzheimer's disease, stroke, myocardial infarction, ischemia reperfusion injury, atherosclerosis, brain trauma, multiple sclerosis, cerebral malaria, sepsis, septic shock, toxic shock syndrome, fever, myalgias due to HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, the herpes viruses or herpes zoster infection in a mammal comprising administering an effective amount a compound as described above.

Substituted heterocyclic compounds and methods of use

The present invention relates to compounds having the general formulaor a pharmaceutically acceptable salt thereof, wherein Ris a saturated or unsaturated 5-, 6- or 7-membered, ring containing 0, 1, 2 or 3 atoms selected from N, O and S, wherein the ring may be fused with a benzo group, and is substituted by 0, 1 or 2 oxo groups, and wherein Ris additionally substituted; and Ris a substituted Calkyl. Also included is a method of prophylaxis or treatment of inflammation, rheumatoid arthritis, Pagets disease, osteoporosis, multiple myeloma, uveititis, acute or chronic myelogenous leukemia, pancreatic &#x3b2; cell destruction, osteoarthritis, rheumatoid spondylitis, gouty arthritis, inflammatory bowel disease, adult respiratory distress syndrome (ARDS), psoriasis, Crohn's disease, allergic rhinitis, ulcerative colitis, anaphylaxis, contact dermatitis, asthma, muscle degeneration, cachexia, Reiter's syndrome, type I diabetes, type II diabetes, bone resorption diseases, graft vs. host reaction, Alzheimer's disease, stroke, myocardial infarction, ischemia reperfusion injury, atherosclerosis, brain trauma, multiple sclerosis, cerebral malaria, sepsis, septic shock, toxic shock syndrome, fever, myalgias due to HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, the herpes viruses or herpes zoster infection in a mammal comprising administering an effective amount a compound as described above.

Growing community of inventors

Thousand Oaks, CA, United States of America

Fang-Tsao Hong